Answers are grounded in this paper and cite their sources.
Introduction: Myotonic Dystrophy Types 1 and 2 (DM1 and DM2) are progressive neuromuscular disorders that compromise functional independence. Occupational therapy depends on psychometrically sound outcome measures—tools that are reliable, valid, and sensitive to change—to monitor progression and intervention efficacy in activities of daily living. Methods: This scoping review followed PRISMA-ScR guidelines. A systematic search of PubMed, Embase, CINAHL, Scopus, Web of Science, and PsycINFO covered 1 January 1998 to 13 January 2026. Adult populations (>18 years) with DM1 or DM2 were included; pediatric and congenital cases were excluded to keep the focus on adult vocational and independent-living roles. Results: Analysis of 38 studies identified disease-specific tools such as the Myotonic Dystrophy Health Index (MDHI) and the Myotonic Dystrophy Type 1 Activity and Participation Scale (DM1-Activ). The MDHI shows excellent reliability (ICC = 0.95), whereas performance-based measures such as the Motor Function Measure exhibit ceiling effects among high-functioning patients. Conclusion: The available evidence favors disease-specific instruments, such as the DM1-Activ, which may help mitigate ceiling effects. For DM2, the evidence base remains limited: the recently developed and validated DM2 Health Index still awaits independent replication and longitudinal responsiveness data, and generic instruments of attenuated sensitivity continue to be widely relied upon.
No takes yet. Share an insight, caveat, or question.
Lazogkas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: